Clinical Findings, Response to Steroid Treatment, and Recurrence Rate in Alopecia Areata Patients with or without a Nonsynonymous Variant of Coiled-Coil Alpha-Helical Rod Protein 1
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Alopecia areata (AA) is considered complex genetic and tissue-specific autoimmune disease. We recently discovered a nonsynonymous variant in the coiled-coil alphahelical rod protein 1 (CCHCR1) gene within the AA risk haplotype. And a water avoidance stress test on CCHCR1 knockout mice induced AA-like lesions. Objective: To investigate the difference clinical findings of AA in patients with the CCHCR1 variant and without. Methods: We conducted a retrospective analysis of the data from 142 AA patients. Among these patients, 20 (14.1%) had a variant of CCHCR1. We evaluated the sex distribution of the patients, age at onset, distribution of the clinical types, prevalence of a positive family history of AA, prevalence of association of AA with atopic dermatitis, response to steroid therapy, and recurrence rate. We used multivariate logistic regression analysis and Fisher’s exact test for statistical analysis. We also investigate electron microscopic observations of hair samples with the CCHCR1 variant and without. Results: The results showed a significant correlation between the CCHCR1 variant and the recurrence rate compared with the variant-negative group (p=0.0072). Electron microscopy revealed abnormalities in the hair shaft structure and hair cuticle in patients with the CCHCR1 variant (p=0.00174). Conclusion: Our results suggest that AA with CCHCR1 variant is clinically characterized by a high recurrence rate and hair morphological abnormality
Abstract
Background: Alopecia areata (AA) is considered complex genetic and tissue-specific autoimmune disease. We recently discovered a nonsynonymous variant in the coiled-coil alphahelical rod protein 1 (CCHCR1) gene within the AA risk haplotype. And a water avoidance stress test on CCHCR1 knockout mice induced AA-like lesions. Objective: To investigate the difference clinical findings of AA in patients with the CCHCR1 variant and without. Methods: We conducted a retrospective analysis of the data from 142 AA patients. Among these patients, 20 (14.1%) had a variant of CCHCR1. We evaluated the sex distribution of the patients, age at onset, distribution of the clinical types, prevalence of a positive family history of AA, prevalence of association of AA with atopic dermatitis, response to steroid therapy, and recurrence rate. We used multivariate logistic regression analysis and Fisher’s exact test for statistical analysis. We also investigate electron microscopic observations of hair samples with the CCHCR1 variant and without. Results: The results showed a significant correlation between the CCHCR1 variant and the recurrence rate compared with the variant-negative group (p=0.0072). Electron microscopy revealed abnormalities in the hair shaft structure and hair cuticle in patients with the CCHCR1 variant (p=0.00174). Conclusion: Our results suggest that AA with CCHCR1 variant is clinically characterized by a high recurrence rate and hair morphological abnormality
참고문헌 (27)
- Wasserman D, "Alopecia areata", Int J Dermatol, 46, pp.121~131 (2007)
- Safavi KH, "Incidence of alopecia areata in Olmsted County, Minnesota, 1975through 1989", Mayo Clin Proc, 70, pp.628~633 (1995)
- Oka A, "Alopecia areata susceptibility variant in MHC region impacts expressions of genes contributing to hair keratinization and is involved in hair loss", EBioMedicine, 57, pp.102810~ (2020)
- Petukhova L, "Genome-wide association study in alopecia areata implicates both innate and adaptive immunity", Nature, 466, pp.113~117 (2010)
- Betz RC, "Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci", Nat Commun, 6, pp.5966~ (2015)
- Forstbauer LM, "Genome-wide pooling approach identifies SPATA5as a new susceptibility locus for alopecia areata", Eur J Hum Genet, 20, pp.326~332 (2012)
- Zhao Q, "The alopecia areata phenotype is induced by the water avoidance stress test in cchcr1-deficient mice", Biomedicines, 9, pp.840~ (2021)
- Fukuyama M, "Alopecia areata : current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines", J Dermatol, 49, pp.19~36 (2022)
- Kanda Y, "Investigation of the freely available easy-to-use software 'EZR' for medical statistics", Bone Marrow Transplant, 48, pp.452~458 (2013)
- Rencz F, "Alopecia areata and health-related quality of life : a systematic review and meta-analysis", Br J Dermatol, 175, pp.561~571 (2016)
- Alkhalifah A, "Alopecia areata update : part I. Clinical picture, histopathology, and pathogenesis", J Am Acad Dermatol, 62, pp.177~188 (2010)
- Tosti A, "Alopecia areata : a long term followup study of 191 patients", J Am Acad Dermatol, 55, pp.438~441 (2006)
- De Waard-van der Spek FB, "Juvenile versus maturity-onset alopecia areata--a comparative retrospective clinical study", Clin Exp Dermatol, 14, pp.429~433 (1989)
- 유혜린, "Factors Associated with Severity of Alopecia Areata", Annals of Dermatology, 29(5), pp.565~570 (2017), 대한피부과학회
- Mohan GC, "Association of vitiligo and alopecia areata with atopic dermatitis : a systematic review and meta-analysis", JAMA Dermatol, 151, pp.522~528 (2015)
- Goh C, "Profile of 513 patients with alopecia areata : associations of disease subtypes with atopy, autoimmune disease and positive family history", J Eur Acad Dermatol Venereol, 20, pp.1055~1060 (2006)
- Wang S, "Role of family history in patchy alopecia areata", Dermatol Online J, 24, pp.13030~ (2018)
- Paus R, "A 'hairy' privilege", Trends Immunol, 26, pp.32~40 (2005)
- Paus R, "Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb?", Yale J Biol Med, 66, pp.541~554 (1993)
- Gilhar A, "Lymphocytes, neuropeptides, and genes involved in alopecia areata", J Clin Invest, 117, pp.2019~2027 (2007)
- Fuentes-Duculan J, "Biomarkers of alopecia areata disease activity and response to corticosteroid treatment", Exp Dermatol, 25, pp.282~286 (2016)
- Sakai H, "Terbinafine-induced generalized pustular psoriasis in a patient carrying CARD14 mutation", J Dermatol, 46, pp.e110~e112 (2019)
- Tervaniemi MH, "Centrosomal localization of the psoriasis candidate gene product, CCHCR1, supports a role in cytoskeletal organization", PLoS One, 7, pp.e49920~ (2012)
- Tervaniemi MH, "Intracellular signalling pathways and cytoskeletal functions converge on the psoriasis candidate gene CCHCR1 expressed at P-bodies and centrosomes", BMC Genomics, 19, pp.432~ (2018)
- Corbi N, "RNA polymerase II subunit 3 is retained in the cytoplasm by its interaction with HCR, the psoriasis vulgaris candidate gene product", J Cell Sci, 118(Pt 18), pp.4253~4260 (2005)
- Brenner LN, "Analysis of glucocorticoid-related genes reveal CCHCR1as a new candidate gene for type 2 diabetes", J Endocr Soc, 4, pp.bvaa121~ (2020)
- Tiala I, "The CCHCR1(HCR)gene is relevant for skin steroidogenesis and downregulated in cultured psoriatic keratinocytes", J Mol Med(Berl), 85, pp.589~601 (2007)